OMER Call Spread Buyers Net 26.4% in a Day as FDA Approval Sparks Bullish Surge
Click to View this Strategy in OMER Option Chain Profit Calculator
Large Call Spread Trade Nets $0.35 Per Share in a Single Morning
On December 24, 2025, a major options trade hit Omeros (OMER): a 1,440-contract call spread went through at a VWAP of $1.33. Just 45 minutes later, the spread’s mid-price surged to $1.68, translating to a $0.35 or 26.4% gain for buyers. What’s more, the OMER stock price rocketed $0.68 higher during this window—making this a trade with near-perfect timing.
| Spread Details | Value |
|---|---|
| Expiration | 16-Jan-26 (23 days) |
| Strike Prices | 12/15 Call Spread |
| Contracts | 1,440 |
| VWAP Trade Price | $1.33 |
| VWAP Bid / Ask | $0.92 / $1.77 |
| Stock Price at Trade | $14.11 |
| Gain Since Trade | $0.35 (+26.4%) |
| Current Stock Price | $14.79 |
View details and analysis of OMER multi-leg trades here.
Buyers Positioned for a $121K Max Profit—Here’s the Strategy
The structure is a classic bullish call spread: buyers paid just over $95,000 for the position. If OMER closes at $15 or higher at expiration on January 16, 2026, the payout grows to about $121,000. With shares now only $0.21 away from the upper strike and a fresh catalyst on the books, the window for max profit is in clear view.
Want to monitor more multi-leg trades like this? Browse large spread trades with the Multi-Leg Option Trade Screener.
Technical Signals Are Strongly Bullish after a 401% Rally from Lows
| Indicator | Current Value |
|---|---|
| Stock Price | $14.79 |
| 1-Day % Change | +69.03% |
| From 52-Week Low | +401.4% |
| From 20-Day MA | +48.6% |
| From 50-Day MA | +72.0% |
| From 250-Day MA | +129.2% |
| 1-Year vs. SPY | OMER: +46.5% | SPY: +17.2% |
| 3-Month vs. SPY | OMER: +246.0% | SPY: +4.3% |
| Uptrend? | Yes — Outperformed SPY in all periods |
OMER has exploded off its lows, breaking through resistance with today’s move. The technical uptrend is obvious: price is far above all moving averages, and the stock has outperformed the market in every timeframe—from 2 weeks to 3 years. Momentum here is undeniable.
Here’s a look at performance over time:
| Duration | OMER Return | Low | High | SPY Return |
|---|---|---|---|---|
| Today | +70.1% | 13.92 | 17.65 | +0.3% |
| 2 Week | +29.7% | 8.27 | 17.65 | +1.3% |
| 1 Month | +67.8% | 8.27 | 17.65 | +5.0% |
| 3 Month | +247.7% | 4.06 | 17.65 | +4.3% |
| 6 Month | +366.5% | 2.95 | 17.65 | +15.6% |
| 1 Year | +47.2% | 2.95 | 17.65 | +17.2% |
| YTD | +50.6% | 2.95 | 17.65 | +18.9% |
| 3 Year | +485.8% | 0.92 | 17.65 | +85.6% |
| 5 Year | +0.3% | 0.92 | 23.85 | +96.6% |
Option Skew Indicator Registers a Bullish 76% Rank
On the options front, OMER’s 30-day implied volatility skew is at a 76% rank—a level that Market Chameleon’s model interprets as bullish compared to the past year. In essence, option traders are piling on to the upside, anticipating more than just a one-day wonder.
FDA Approval of YARTEMLEA Fuels Positioning—What’s Next?
The trade aligns with a major fundamental catalyst: FDA approval of YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). With clinical data showing survival improvements and no boxed warning, the drug’s green light triggered a wave of buying—across both stock and options.
The company’s conference call, scheduled for December 29, 2025, will be closely watched for launch plans and revenue outlook. The approval also positions Omeros for a broader US roll-out in January and a major European regulatory decision in mid-2026.
Key Takeaways: Bullish Data, But Risks Remain
With OMER shares blowing through resistance and option sentiment flashing green, this spread buyer looks to have caught the right wave. Still, as always, rapid moves on fresh news can snap back—especially in biotech. For those tracking unusual options activity, this trade is an instructive example of how catalysts and positioning collide.
Want to see more actionable options strategies? You can follow similar trades—and screen for new multi-leg opportunities—at Multi-Leg Option Trades Screener.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI